Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7261 to 7275 of 7711 results

  1. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued [GID-MT563]

  2. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

  3. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

  4. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC

  5. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

  6. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

  7. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

  8. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

  9. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

  10. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

  11. Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)

    This guideline has been updated and replaced by NICE guideline NG240.

  12. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    In development [GID-TA11252] Expected publication date: TBC

  13. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    In development [GID-TA11109] Expected publication date: TBC

  14. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    In development [GID-TA11264] Expected publication date: TBC

  15. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development [GID-TA11010] Expected publication date: TBC